Suscribirse

AUTOIMMUNE LIVER DISEASE : Current Standards, Future Directions - 03/09/11

Doi : 10.1016/S1089-3261(05)70167-7 
Robert G. Gish, MD a, Andrew Mason, MD b
a Departments of Medicine and Transplantation, California Pacific Medical Center, San Francisco, California (RGG) 
b Department of Medicine, Section of Gastroenterology and Hepatology, Ochsner Clinic and Medical Foundation, New Orleans, Louisiana (AM) 

Resumen

Autoimmune hepatitis (AIH) comprises a relatively diverse group of liver diseases associated with autoantibody formation (Figure 1) which are thought to occur as a result of an uncontrolled, self-directed inflammatory attack on hepatocytes or bile ducts. The immune injury commonly leads to rapidly progressive liver disease, progressive fibrosis, and ultimately cirrhosis. The cause of autoimmune liver disease is not known, but factors that influence the development of clinical disease include genetic predisposition, prior liver injury caused by viruses, environmental exposure to toxins, and, possibly, ongoing infectious factors, including viruses.

The incidence and prevalence of the forms of autoimmune liver diseases remain to be defined worldwide, although information is available for distinct ethnic populations.27 The point prevalence of autoimmune liver disease ranges from 13 to 20/100,000 population and the incidence from 1 to 2/100,000 in a Norwegian population.35

Improving the understanding of autoimmune liver disease will allow physicians and other medical practitioners to make decisions about the proper type of therapy to prevent progressive liver disease and may ultimately eliminate death from liver failure and the need for liver transplantation. Other focuses of therapy include improving quality of life preventing primary septic complications caused by biliary strictures (in primary sclerosing cholangitis) and infectious complications of immune suppression.

Serologic assays, biochemical tests, histologic criteria, and imaging tests have provided the basis for the diagnosis of autoimmune liver disease. Recent advances in serologic testing, genetic studies, and immunohistochemistry may provide more rapid and accurate diagnosis of patients with autoimmune liver disease and may also guide the cause of immunosuppressive therapy.

Infectious causes of autoimmune liver disease have been proposed, with prior viral hepatitis A, B, or C, cytomegalovirus (CMV), paramyxovirus, and most recently retrovirus infections suggested as possibilities.108, 111 The development of recurrent AIH, primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) in liver transplant recipients provides strong support for an infectious origin for of these disorders. If environmental agents are found to be the cause or a component of disease activity and progression, advances in antibiotic and antiviral therapies may also delay or prevent progressive liver disease.

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to Robert G. Gish, MD 2340 Clay Street Room 223 California Pacific Medical Center San Francisco, CA 94115 e-mail: [email protected]
Financial Support: ALM supported by a Hepatology Seed Grant for Primary Biliary Cirrhosis from the American Liver Foundation, and AI01467 from the National Institute for Health.


© 2001  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.© 1993 
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 5 - N° 2

P. 287-314 - mai 2001 Regresar al número
Artículo precedente Artículo precedente
  • PREFACE
  • ROBERT G. GISH
| Artículo siguiente Artículo siguiente
  • HEPATIC FIBROSIS : Pathogenesis and Principles of Therapy
  • Efsevia Albanis, Scott L. Friedman

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.